Prelude Therapeutics (Prelude Therapeutics) Beta : 1.24 (As of Apr. 30, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Prelude Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-04-30), Prelude Therapeutics's Beta is 1.24.

Prelude Therapeutics Beta Historical Data

The historical data trend for Prelude Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prelude Therapeutics Beta Chart

Prelude Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beta

Get a 7-Day Free Trial

0.98

Prelude Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beta	Get a 7-Day Free Trial															-	-	-	0.40	0.98

Competitive Comparison of Prelude Therapeutics's Beta

For the Biotechnology subindustry, Prelude Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prelude Therapeutics's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Prelude Therapeutics's Beta falls into.

Prelude Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Prelude Therapeutics (NAS:PRLD) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Prelude Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of Prelude Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.

Prelude Therapeutics (Prelude Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prelude Therapeutics Inc (NAS:PRLD) » Definitions » Beta

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Powder Mill Road, Wilmington, DE, USA, 19803

Website

https://www.preludetx.com

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Executives

Krishna Vaddi	director, officer: President, CEO	C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803
Bryant David Lim	officer: Chief Legal Counsel, Corp Sec.	C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Laurent Chardonnet	officer: Chief Financial Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita	director, 10 percent owner	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jane Huang	officer: President, CMO	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Deborah Morosini	officer: EVP, Chief of Clinical Affairs	C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803
Andrew Combs	officer: EVP, Head of Chemistry	C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803
David J Mauro	officer: Chief Medical Officer	36 TERRELL DRIVE, WASHINGTON CROSS PA 18977